Monogram Orthopaedics


Raised to Date: Raised: $23,648,853

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Preferred


Series A

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


# of Investors


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Austin, Texas

Business Type


Monogram Orthopaedics, a medical technology company, is raising funds on StartEngine through Reg A+ crowdfunding. The company is developing a product solution architecture to allow personalization of orthopedic implants. Monogram Orthopaedics is using 3D printing and robotics through automated digital image analysis algorithms. Dr. Douglas Unis founded Monogram Orthopaedics in 2016. The proceeds of the current round of funding, with no minimum target and a maximum target of $30,000,000, will be used to fund the development and pre-market submission of the Monogram total knee and robotic system. Monogram Orthopaedics has established a product-market fit and expects to start generating revenue by 2021.

Balance Sheet

Cash and Cash Equivalents


Investment Securities


Accounts and Notes Receivable


Property, Plant and Equipment (PP&E)


Total Assets


Accounts Payable & Accrued Liabilities


Long Term Debt


Total Liabilities


Total Stockholders' Equity


Total Liabilities and Equity


Statement of Comprehensive Income Information

Total Revenues


Costs & Expenses Applicable to Rev


Depreciation and Amortization


Net Income


Earnings Per Share - Basic


Earnings Per Share - Diluted


Auditor: Fruci and Associates II, PLLC
Financials as of: 01/16/2021
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Monogram Orthopedics 05/22/2023 Dealmaker Securities $246,000,000 $15,958,364 Equity - Common Funded RegA+
Monogram Orthopedics 04/27/2023 Republic $246,000,000 $233,363 Equity - Common Funded RegA+
Monogram Orthopedics 03/15/2023 Dealmaker Securities $155,000,000 $4,599,145 Equity - Preferred Funded RegCF
Monogram Orthopaedics 02/17/2022 StartEngine $89,000,000 $23,648,853 Equity - Preferred Funded RegA+
Monogram Orthopaedics 01/15/2021 StartEngine $89,900,000 $2,965,501 Equity - Preferred Funded Test the Waters / RegA+
Monogram Orthopaedics 03/30/2020 SeedInvest $21,250,000 $14,588,668 Equity - Preferred Funded RegA+
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article


Last year, KingsCrowd rated Monogram Orthopaedics as a Deal to Watch. In that round, it raised $14 million through a Regulation A+ campaign. Now, this medtech company is back for another round. 

Most early-stage companies focus on refining and perfecting one product or service. Monogram Orthopaedics has two — its 3D-printed hip and knee replacement implants and its ‘state-of-the-art’ surgical robot. The robot helps doctors by using advanced imaging to mill cavities inside a person’s bones. The purpose here is to aid in the installation of patient implants. The surgical robot boasts seven degrees of freedom, variable arm speed, and a high-efficiency cutting system. It’s also capable of sensing small changes in force. All of these features are valuable in dealing with delicate surgical procedures. They also help to reduce damage to the bones that often occur when certain surgical processes are conducted manually.

The company’s implants are a different animal entirely. As opposed to the traditional one-size-fits-all implants that flood the market, Monogram Orthopaedics has come up with a new type of device. For each patient, the business conducts a CT-scan of their knees and/or hips. It then uses its own AI technology to design a customized implant that is then 3D printed specifically for that patient. The surgical robot then helps to install the implant.

The idea of a customized implant addresses several problems that exist in the space. For starters, customized fittings should reduce the number of implant failures that occur each year — currently about 10% of all knee implants and 15% of hip replacements fail. Second, while just 3% of hip replacements use cement as part of their installation process, this figure for knee implants is 92%. Between the advantages the customized implants offer and the precision the company’s robot can provide, Monogram can promote what’s called natural biologic fixation. What this means is that instead of cementing the implants where they need to be, the customized fit they offer gets them close enough to a perfect fit to allow the bones to lock them into place. This, management alleges, will be especially beneficial for younger, more active patients.

Monogram Orthopaedics has several different revenue strategies for their products moving forward. This includes selling both their navigated robot system and their cutting system. Consumables they can sell include their implants, specific navigation consumables, and drilling tools. Management also intends to look into licensing and service opportunities for their technologies. With eight patents filed for, this could lead to a lot of different revenue streams for the business down the line.

Monogram Orthopaedics’ current StartEngine raise has been rated a Deal to Watch by the KingsCrowd investment team.

Next Section: Price


In order to take Monogram Orthopaedics to the next level, management is hoping to raise a significant amount of cash. In all, the firm hopes to close a round of funding in the amount of $30 million. This follows a $14.59 million round in March 2020 and a $2.97 million private round closed last month. The company hopes to achieve this new, higher round by issuing common stock valued at $6.27 per unit. The valuation management is asking investors to accept is $75 million on a pre-money basis. That amount is quite high for a business that still has not generated any revenue.

Next Section: Market


The market opportunity for Monogram Orthopaedics is not particularly large, though it is healthy. According to one source, the hip replacement market in 2018 was worth $7.13 billion globally. By 2026, it’s expected to climb to $10.51 billion. This implies an annual growth rate of 5%. The largest market for hip replacements right now is North America at $2.52 billion. The knee replacement market is even larger. Our source pegs the opportunity at $9 billion in 2019. By 2026 it should climb to $16.2 billion. That’s based on an annualized growth rate of 34.7%. The largest market opportunity is in the US specifically. Our source puts the US opportunity at about $4.64 billion.

A broader way to look at the opportunity is to look at the joint reconstructive device market. One source we found pegs the space at about $19.38 billion as of 2017. With an annualized growth rate of 5.1%, the expectation is for the industry to rise to $28.47 billion by 2025. There is also the robotic surgery aspect to the business. One source we dug up indicated that this opportunity was worth about $6 billion in 2020. By 2025, it should rise to $11.1 billion based on an annualized growth rate of 13.1%.

All in all, there is plenty of room for Monogram Orthopaedics to carve out a healthy niche for itself.

Next Section: Team


Monogram Orthopaedics has an extensive team working on it. At present, in fact, the company has 16 full-time employees and at least four contractors. At the helm of the business, though, are its two co-founders: Dr. Douglas Unis and Benjamin Sexson. Dr. Unis currently serves as the company’s CMO (Chief Medical Officer). He also works as a Board-Certified Attending Orthopaedic Surgeon at Mount Sinai Health System. He has also held other roles, such as Chief of Quality Improvement at Mount Sinai West and Surgical Consultant at an unnamed think tank. His medical experience — particularly his emphasis on orthopaedic surgery — is excellent to see. 

Sexson, meanwhile, operates as Monogram Orthopaedics’ CEO. Previously, he founded and was the CEO of Brides & Hairpins. Before that, he was the Director of Business Development at Pro-Dex Inc. He has also worked as a VP of PPRR Modeling and Analytics for the Corporate Treasury at MUFG Americas. None of this experience relates to orthopaedics. However, Sexson does bring business acumen and entrepreneurial experience — both important attributes for Monogram’s potential success.

Next Section: Differentiators


Differentiation is perhaps one of the most difficult aspects to view the business from. On one hand, its customized, 3D-printed implants and the robotic surgical machine are clearly superior to the bulk of what is on the market today. Analysts seem to agree that the future of surgery is robotic in nature. One source, for instance, says that by 2027 50% of knee replacement surgeries will be done using robotic assistants — a substantial increase from just 11% in 2019. While Monogram Orthopaedics is different from the majority of the market, though, it’s not the only player in this space.

The market leader in knee and hip replacements is a giant named Stryker. In 2019, the company’s orthopedics segment generated revenue of $5.28 billion. In this, its knee implant business generated revenue of $1.82 billion, while its hip replacement unit generated sales of $1.38 billion. In the US, its knee business was $1.35 billion in size, while its hips business was $882 million. If Stryker were focused solely on the old way of conducting these procedures, it wouldn’t be worrisome. But in recent years the company has made solid strides in the same direction that Monogram Orthopaedics is focused on.

Its Mako robot, for instance, boasts more than 1,000 installations since launch. This device operates as a CT-based preoperative planning machine. The company is also focused on customized, 3D-printed implants for both knees and hips. In fact, the firm recently invested $225.8 million toward a facility expansion dedicated to R&D on this market. And in November of 2020 it acquired Wright Medical for $5.4 billion. Wright Medical designs implants and technologies to help with the extremities of the human body. This competition from Stryker should be worrisome for shareholders in Monogram Orthopaedics.

Next Section: Performance


Since we last wrote about Monogram Orthopaedics, the company has had some nice traction. True, it is still pre-revenue and generating net losses. However, management is forecasting that it can begin to monetize its implants this year. It has already executed agreements with two different distributors. This process was vastly accelerated by the ability of the firm to open up a cadaver lab of its own in November of last year. There, the company has performed surgeries using its devices. Monogram is also going to be presenting its product system to the American Academy of Orthopaedic Surgeons in August of this year. Though it is still quite far behind Stryker at this time, this progress is encouraging. In addition, it would be a boon for shareholders if the company can begin generating revenue this year.

Next Section: Other

Bearish Outlook

At present, there are some bearish things for investors to be aware of. For starters, the company’s valuation is awfully high. It’s one of the highest we have seen, and it’s exceptionally high for a business with no revenue. The market opportunity is neither particularly large nor small. In addition, investors should expect the business to have to raise additional funds in the future, which will serve to dilute investors further over time. There is also growing and significant competition from the industry leader, Stryker. That’s definitely an issue to be concerned over.

Next Section: Bullish Outlook

Bullish Outlook

Monogram Orthopaedics has a strong bullish case. It’s clear from the data that the company’s business model is the way the industry is moving. It’s certainly one of the earlier movers and, as such, has the opportunity to fare well. The industry is growing at a nice clip, and the company’s management team is robust. Throw in its filed patents and the prospect that revenue generation should begin this year, and it’s difficult not to see this as an interesting and viable prospect.

Next Section: Executive Summary

Executive Summary

At this moment, the data paints a rather interesting picture of a business in a race against time. The situation involving Stryker is especially worrisome, but on the whole Monogram Orthopaedics looks to be an appealing prospect. After all, the industry does have room for more than one winner. In a sense, Stryker is proving what kind of market opportunity really does exist for Monogram Orthopaedics. Management’s traction in recent months is also a plus. Taken all together, Monogram Orthopaedics remains a Deal to Watch at this time.

For questions regarding the KingsCrowd staff pick or ratings for this company, please reach out to

Analysis written by Daniel Jones.

Founder Profile

Monogram Orthopaedics Founder Dr. Douglas Unis on the Future of Joint Replacements

Knee and hip replacement surgery is a painful and expensive process. Furthermore, there are many risks associated with these surgeries — including infection, improper healing, and failure of the replacement material. There is a clear market need for better joint replacements and better surgical procedures.

Monogram Orthopaedics was founded to address this need. The company is developing personalized orthopedic implants using 3D printing and robotic surgery. We reached out to founder Dr. Douglas Unis to learn more about this exciting medical advancement.

Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.

Read Founder Interview

Company Updates

Great news. Monogram Orthopaedics is going public on May 18! The company is going to list on the Nasdaq under the ticker MGRM.

The company will go public at $7.25 per share. But don’t worry if this price seems low. Monogram recently completed a two-for-one stock split. So the split-adjusted stock price is actually $14.50, valuing the company at $246 million.

View Company Update

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Monogram Orthopaedics on StartEngine
Platform: StartEngine
Security Type: Equity - Preferred
Valuation: $89,000,000
Price per Share: $6.27

Follow company

Follow Monogram Orthopaedics on StartEngine

Buy Monogram Orthopaedics's Deal Report

Warning: according to the close date for this deal, Monogram Orthopaedics may no longer be accepting investments.

Monogram Orthopaedics Deal Report

Get KingsCrowd’s comprehensive report on Monogram Orthopaedics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Monogram Orthopaedics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the Monogram Orthopaedics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge